A Phase 3, Open‑label Study Evaluating the Long‑term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 Months of Age and Older

Project Details

StatusActive
Effective start/end date25/09/24 → 1/07/25

Funding

  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$81,000.00